NEW YORK – Twist Bioscience announced on Wednesday after the close of the market the pricing of an upsized $300 million public offering of common stock at $110 per share.
The South San Francisco, California-based firm will offer approximately 2.8 million shares, including 75,000 shares to be sold by certain shareholders.
Twist has granted the underwriters a 30-day option to purchase up to an additional 409,090 shares at the public offering price, less the underwriting discount and commissions.